Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

Post time Half hour(s) ago

journal：Journal of Clinical Oncology

Authors：Mitesh J. Borad; Alison M. Schram; Richard D. Kim; Suneel Deepak Kamath; Vaibhav Sahai; Efrat Dotan; Robin Kate Kelley; Mariano Ponz-Sarvise; Do-Youn Oh; Jeffrey Yachnin; Vaia Florou; Philippe Alexandre Cassier; Joon Oh Park; Chih-Yi Liao; Michael Millward; Florence (Tianhui) Ramirez; Fabien Jean Ricard; Antoine Hollebecque; Vivek Subbiah; Lipika Goyal

Published date：2023-6-1

DOI：10.1200/jco.2023.41.16_suppl.4009

PDF link：https://ascopubs.org/doi/pdfdire ... 23.41.16_suppl.4009

Article link：https://doi.org/10.1200/jco.2023.41.16_suppl.4009

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

[Other] Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors. Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.